ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 0608 • ACR Convergence 2025

    Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients

    Elena Heras Recuero1, Antia Garcia Fernandez2, Cristina Gomez-Moreno3, Ivan Ferraz Amaro4, Javier Llorca5 and Miguel A. González-Gay6, 1Hospital Fundacion Jimenez Dias, Madrid, Spain, 2Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 3Fundacion Jiménez Díaz School of Nursing, Madrid, Autonomous University Madrid, Madrid, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, 6Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain

    Background/Purpose: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous…
  • Abstract Number: 1310 • ACR Convergence 2025

    Naturalized Language Processing Based Extraction of Rheumatoid Arthritis Disease Activity Measures from the Electronic Health Record

    Elizabeth Park1, Iram Kamdar2, Reid Weisberg1, Andy Nguyen1, Joan Bathon3, Jon Giles4, Chunhua Weng5 and Elana Bernstein1, 1Columbia University Irving Medical Center, New York, NY, 2Columbia University Data Science Institute, New York, NY, 3Columbia University, NEW YORK, NY, 4Cedars-Sinai Medical Center, New York, NY, 5Columbia University Department of Biomedical Informatics, New York, NY

    Background/Purpose: A treat-to-target approach in rheumatoid arthritis (RA) requires intense monitoring of RA disease activity with measures such as the clinical disease activity index (CDAI).…
  • Abstract Number: 1430 • ACR Convergence 2025

    Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis

    Stylianos Georgiadis1, Lykke Ørnbjerg1, Brigitte Michelsen2, Tore K. Kvien2, Mehrdad Shoae Kazemi1, Bente Glintborg1, Anne Gitte Loft3, Rita Fonseca4, Helena Santos5, Andreas Reich6, Anne C. Regierer6, Jarno Rutanen7, Laura Kuusalo8, Gary Macfarlane9, Gareth T. Jones9, Adrian Ciurea10, Michael J. Nissen11, Bjorn Gudbjornsson12, Olafur Palsson13, Ziga Rotar14, Katja Perdan Pirkmajer15, Daniela Di Giuseppe16, Merete Hetland17 and Mikkel Ostergaard18, 1Rigshospitalet, Glostrup, Denmark, 2Diakonhjemmet Hospital, Oslo, Norway, 3Aarhus University Hospital, Aarhus, Denmark, 4Unidade Local de Saúde de Entre Douro e Vouga, Santa Maria da Feira, Portugal, 5Instituto Português de Reumatologia, Lisbon, Portugal, 6German Rheumatology Research Center, Berlin, Germany, 7Tampere University Hospital, Tampere, Finland, 8Turku University Hospital, Turku, Finland, 9University of Aberdeen, Aberdeen, United Kingdom, 10University Hospital Zurich, Zurich, Switzerland, 11Geneva University Hospital, Geneva, Switzerland, 12Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13University of Iceland, Reykjavik, Iceland, 14University Medical Centre Ljubljana, Ziri, Slovenia, 15University Medical Centre Ljubljana, Ljubljana, Slovenia, 16Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Stockholms Lan, Sweden, 17Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, 18Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark

    Background/Purpose: In patients with axial spondyloarthritis (axSpA), high disease activity is a key indication for biological disease-modifying antirheumatic drug (bDMARD) initiation. The Axial Spondyloarthritis Disease…
  • Abstract Number: 1566 • ACR Convergence 2025

    Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis

    Ellen Romich1, Alexis Ogdie2, Peter Merkel3, Alisa Stephens Shields3, Jessica Alvey4, Shervin Assassi5, Elana Bernstein6, Sonali Bracken7, Flavia Castelino8, Lorinda Chung9, Luke Evnin10, Tracy Frech11, Jessica Gordon12, Faye Hant13, Monica Harding14, Laura Hummers15, Dinesh Khanna16, Kimberly Lakin12, Dorota Lebiedz-Odrobina14, Yiming Luo6, Ashima Makol17, Maureen Mayes18, Zsuzsanna McMahan19, Jerry Molitor20, Duncan Moore21, Carrie Richardson22, Ami Shah15, Ankoor Shah23, Brian Skaug24, Virginia Steen25, John VanBuren14, Elizabeth Volkmann26, Carleigh Zahn16 and Nora Sandorfi3, 1University of Pennsylvania, Media, PA, 2Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, 3University of Pennsylvania, Philadelphia, PA, 4Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, 5Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, 6Columbia University, New York, NY, 7Duke University Medical Center, Durham, NC, USA, Apex, NC, 8Massachusetts General Hospital, Boston, MA, 9Stanford University, Stanford, CA, 10Scleroderma Research Foundation, San Francisco, CA, 11Vanderbilt University Medical Center, Nashville, TN, 12Hospital for Special Surgery, New York, NY, 13Medical University of South Carolina, Charleston, SC, 14University of Utah, Salt Lake City, UT, 15Johns Hopkins Rheumatology, Baltimore, MD, 16University of Michigan, Ann Arbor, MI, 17Mayo Clinic, Rochester, MN, 18UT Health Houston Division of Rheumatology, Houston, TX, 19UT Health Houston, Houston, TX, 20University of Minnesota, Minneapolis, MN, 21Northwestern Memorial Hospital, Chicago, IL, 22Northwestern University, Chicago, IL, 23Duke University, Durham, NC, 24UTHealth Houston Division of Rheumatology, Houston, TX, 25Georgetown University School of Medicine, Washington, DC, 26Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA

    Background/Purpose: Global assessments by patients and physicians provide unique but complementary perspectives of disease severity. This study aimed to determine the clinical and patient-reported factors…
  • Abstract Number: 2148 • ACR Convergence 2025

    Initial MRI Findings as Predictors of Disease Phenotype in Juvenile Dermatomyositis: A Comparative Study of Myositis Specific Antibodies NXP2-Positive and Myositis Specific Antibody-Negative Patients in a Large Tertiary Hospital

    Juan Torres Sanchez1, Pritish Bawa2, Andrea Ramirez1, MaiLan Nguyen3, Amit Thakral4, Xiaofan Huang1, J Herman Kan2 and Marietta De Guzman1, 1Baylor College of Medicine, Houston, TX, 2Texas Childrens Hospital, Houston, TX, 3Baylor College of Medicine, Austin, TX, 4Texas Children’s Hospital, Houston, TX

    Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy of childhood, characterized by proximal muscle weakness and distinctive cutaneous findings. Magnetic resonance imaging…
  • Abstract Number: 2349 • ACR Convergence 2025

    Classification of “Difficult-to-Manage Axial Spondyloarthritis”: A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time

    Gözde Sevgi Kart bayram1, Muhammed Çağrı Akdemir2, Mustafa Ekici3, Gizem Ayan4, Büşra Fırlatan Yazgan1, Erdinç Ünaldı3, Buğu Bulat1, Ali Aytuğ Kuştaş3, Ali Akdoğan5, Omer Karadağ5, Şule Apraş Bilgen1, Ali İhsan Ertenli1, Sedat Kiraz3, Umut Kalyoncu1 and Levent Kılıç1, 1Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, 2Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, Ankara, Turkey, 3Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Ankara, Turkey, 4Ankara Research and Training Hospital, Ankara, Turkey, 5Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara

    Background/Purpose: The concept of difficult-to-manage axial spondyloarthritis (D2M-axSpA)[1], may vary over time. Transitions between D2M and non-D2M classifications throughout the disease course remain unclear. This…
  • Abstract Number: 2683 • ACR Convergence 2025

    Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis

    Stevie Barry1, Katie McMenamin2, Austin Wheeler3, Bryant England3, Grant Cannon4, Brian Sauer5, Gary Kunkel6, Katherine Wysham7, Beth Wallace8, Andreas Reimold9, Gail Kerr10, Isaac Smith11, John Richards12, Iris Lee13, Rui Xiao1, Sylvanus Toikumo14, Henry Kranzler14, Rachel Kember14, Scott Damrauer14, Michael Levin14, Michael George1, Ted Mikuls3, Joshua Baker1 and Thomas Riley1, 1University of Pennsylvania, Philadelphia, PA, 2Boston Medical Center, Boston, MA, 3University of Nebraska Medical Center, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 7VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 8Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 9Dallas VA Medical Center, Dallas, TX, 10Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 11Duke University Hospital, Durham, NC, 12Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 13Washington University in St Louis, Saint Louis, MO, 14University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA

    Background/Purpose: Guidelines recommend the use of composite scores to evaluate disease activity in RA and inform a treat-to-target approach. It is recognised that patient-reported components…
  • Abstract Number: 0425 • ACR Convergence 2025

    High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease

    Tahnee Spoden1, Samira Nazzar Romero2, Deborah McCurdy3, Alice Hoftman4, Sangmee Bae5, Jennifer Wang4, Ani Shahbazian4 and Christina Charles-Schoeman6, 1UCLA, Los Angeles, CA, 2Nemours Children's Health, Orlando, 3UCLA Medical Center, Los Angeles, CA, 4UCLA, Los Angeles, 5UCLA Rheumatology, Los Angeles, CA, 6UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Cardiovascular disease remains the leading cause of mortality in patients with Rheumatoid Arthritis (RA). Normally, high density lipoprotein (HDL) acts in a cardioprotective capacity…
  • Abstract Number: 0497 • ACR Convergence 2025

    Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)

    Nariaki Hao and Naoki Kondo, Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital, Niigata, Japan

    Background/Purpose: To retrospectively evaluate drug survival and reasons for discontinuation of eight biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients using the Niigata…
  • Abstract Number: 0620 • ACR Convergence 2025

    The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission

    Luis Daniel Fajardo Hermosillo and María Karina Lizbeth López Ramírez, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, GUADALAJARA, Jalisco, Mexico

    Background/Purpose: Remission in Systemic Lupus Erythematosus (SLE) is described by the Definition of Remission in SLE (DORIS), but it is hardly achieved in clinical practice,…
  • Abstract Number: 1312 • ACR Convergence 2025

    Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department

    Elodie Portier1, Olivier Fogel2, Terkia Medkour3, Sophie Hecquet3 and Jérôme AVOUAC3, 1Rheumatology department, Bicetre hospital, Le Kremlin Bicetre, France, 2AP-HP, Paris, France, 3Rheumatology department, Cochin hospital, Paris, France

    Background/Purpose: The objective of this study was to identify clusters of patients with rheumatoid arthritis (RA) in clinical practice, according to evolution of disease activity…
  • Abstract Number: 1433 • ACR Convergence 2025

    Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort

    Yen-An Chang and Ming-Han Chen, Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China)

    Background/Purpose: The concept of Difficult-to-Manage Axial Spondyloarthritis (D2M-ax-SpA) was recently introduced by the Assessment of Spondyloarthritis International Society (ASAS). According to this new definition, D2M-ax-SpA…
  • Abstract Number: 1608 • ACR Convergence 2025

    Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis

    Peter Merkel1, Arnaud Bourdin2, Bernhard Hellmich3, Nader Khalidi4, David Jackson5, David Jayne6, Parameswaran Nair7, Christian Pagnoux8, Ulrich Specks9, Benjamin Terrier10, Lena Börjesson Sjö11, Priya Jain12, Aadarsh Lal13, Sofia Necander14, Claire Walton15 and Michael Wechsler16, 1University of Pennsylvania, Philadelphia, PA, 2Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, 3Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, 4Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, 5Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, 6University of Cambridge, Cambridge, United Kingdom, 7Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, 8Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, 9Mayo Clinic, Rochester, MN, 10Cochin Hospital, Paris, France, 11Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, 12BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 13Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, 14Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 15Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 16Department of Medicine, National Jewish Health, Denver

    Background/Purpose: Results from the 1-year double-blind period and first year of the open-label extension (OLE) of the MANDARA trial (NCT04157348) demonstrated that over 60% of…
  • Abstract Number: 2158 • ACR Convergence 2025

    Evaluating Nailfold Capillary Changes as Indicators of Disease Activity in Juvenile Dermatomyositis

    Zilan Zheng1, Laila Metni2, Susan Kim3 and Jessica Neely4, 1University of California, San Francisco, San Francisco, CA, 2University of California, Berkeley, Berkeley, CA, 3UCSF Benioff Children's Hospital, San Francisco, CA, 4UCSF, San Francisco, CA

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare pediatric autoimmune myopathy characterized by skin and muscle inflammation, resulting in microvascular changes that can be visualized in…
  • Abstract Number: 2366 • ACR Convergence 2025

    Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs

    Philip J. Mease1, Nicole Middaugh2, Yolanda Muñoz Maldonado2, Chao Song3, Skyler Peterson4, Robert Low3 and Alexis Ogdie5, 1Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 2CorEvitas, LLC, Waltham, MA, 3UCB, Smyrna, GA, 4CorEvitas, LLC, Waltham, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory condition primarily affecting the joints and skin.1 More severe symptoms are associated with lower health-related quality of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 112
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology